ClinicalTrials.Veeva

Menu
C

Clinical Research of Brandon | Brandon, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

AVP-786
ABX464
amlodipine
Simufilam
indapamide
Linaclotide
VX-147
Deudextromethorphan Hydrobromide
Celecoxib
BI 690517

Parent organization

This site is a part of Clinical Research of Brandon

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 19 total trials

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only
Alzheimer Disease
Drug: Simufilam

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Trial sponsors

Otsuka logo
A
A
C
G
Boehringer Ingelheim logo
D
Forest Laboratories logo
Janssen (J&J Innovative Medicine) logo
Kowa logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems